Investigating host dynamics under antibiotic treatments for resistant helicobacter pylori

Abstract

Helicobacter pylori (H. pylori) infection is a major global health issue linked to the onset of chronic gastritis, peptic ulcers, and gastric cancer. Although antimicrobial treatments are widely utilized, the rise of antibiotic-resistant (AMR) H. pylori strains has significantly undermined the effectiveness of these therapies. This study seeks to examine the response of host cells to the antimicrobial medications deployed for H. pylori treatment, especially in cases involving resistant bacterial strains. The research will emphasise two main areas: the cellular reactions of the host to these medications and the possible synergistic effects of combination therapies within the scope of AMR H. pylori infection. Evidence indicates that these drugs, in addition to their intended antibacterial effects, can influence mammalian cells directly, modifying pathways related to inflammation, immune responses, and cellular stress. This study will investigate how these medications affect host cell biology when targeting resistant H. pylori strains, evaluating whether they intensify inflammatory reactions, trigger cytotoxic effects, or alter signalling networks in host cells. Further, the study will assess the potential synergistic impacts of combination therapies on host cells. While these therapies seek to improve bacterial elimination, their unintended consequences for mammalian cells in the context of resistance are still not clearly understood. Through cellular assays, molecular pathway analysis, and synergy modelling, this research will shed light on how combination therapies engage with host cells during infections with resistant H. pylori strains. The results will aid in refining H. pylori treatment strategies by finding a balance between effective bacterial elimination and reducing negative effects on the host, addressing the important challenges that AMR presents in gastric infections.